GlassScriptPhysician profile
Albert Janerich
NPI 1336159508
$7,880.09
in general payments reported to CMS, 2019-2025
33 companies · $557 in 2025
The $557 reported for 2025 was more than what 80% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $325 · 2021: $542 · 2022: $491 · 2023: $400 · 2024: $4,906 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $4,219 · Food and Beverage: $1,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $4,219.40 |
| Food and Beverage | $1,643.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| International Rehabilitative Sciences, INC | $4,219.40 | 2024 | Rs 4i Plus Sequential Stimulator, Rs-Lbg Rs-Fbg |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $828.90 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $750.34 | 2019-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $182.47 | 2024-2025 | General - Pain Management, Infinion 16 |
| Daiichi Sankyo INC. | $152.27 | 2019 | |
| Indivior INC. | $147.46 | 2021-2025 | Sublocade |
| Nevro Corp. | $146.21 | 2024 | Senza |
| Alkermes, INC. | $130.65 | 2019-2024 | Vivitrol |
| Ipsen Biopharmaceuticals, INC | $129.76 | 2019-2025 | Dysport |
| Biodelivery Sciences International, INC. | $124.50 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $120.57 | 2019-2020 | |
| Abbvie INC. | $119.11 | 2022-2025 | |
| Globus Medical, INC. | $101.42 | 2025 | Senza |
| Axonics, INC. | $91.37 | 2022-2023 | Axonics |
| Redhill Biopharma INC. | $69.84 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $65.83 | 2024-2025 | Daxi, Daxxify |
| Medtronic, INC. | $59.64 | 2021 | |
| Allergan, INC. | $55.49 | 2019-2021 | |
| Pfizer INC. | $51.92 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $51.63 | 2023 | Seglentis |
| Almatica Pharma LLC | $38.11 | 2022 | |
| Si-Bone, INC. | $37.86 | 2021 | |
| Shionogi INC | $35.57 | 2019 | |
| Nalu Medical, INC. | $28.75 | 2023 | Nalu Neurostimulation System |
| Teva Pharmaceuticals USA, INC. | $26.78 | 2023 | Austedo Xr |
| Abbott Laboratories | $19.75 | 2022 | |
| Foundation Fusion Solutions, LLC | $16.16 | 2024-2025 | |
| Mdd US Operations, LLC | $15.04 | 2019 | |
| Protega Pharmaceutials INC | $14.40 | 2023 | Roxybond |
| Forte Bio-Pharma LLC | $13.00 | 2021 | |
| Lundbeck LLC | $12.46 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.13 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Janerich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.